Does body mass index and adult height influence cancer incidence among Chinese living with incident type 2 diabetes?
We investigated the site-specific cancer incidence risks among participants living with newly diagnosed type 2 diabetes (T2D) in relation to body mass index (BMI) and height. The sample consisted of 25,130 participants living in Ningbo (China) who were newly diagnosed with T2D between 01/01/2006 and 12/31/2007 but without cardiovascular disease or cancer diagnoses at baseline. Follow-up of the sample was from 01/01/2008 to 12/31/2014. Cancer incidence stratified by BMI categories and quartiles of height were analyzed using standardized incidence ratios (SIR; the ratio of observed to the expected number of diagnosed cases) with 95% confidence intervals (95%CI). Follow-up included 22,795 participants, 155,845 person-years and 1063 cancer diagnoses. Compared with the general population of Ningbo, SIRs of all-cancer were 2.19 (95% CI: 2.01-2.37) for males and 1.80 (95% CI: 1.64-1.96) for females. The all-cancer SIRs for participants in the normal BMI category was 1.13 (95% CI: 1.00-1.38). By comparison, the SIRs for the overweight and obese groups were 0.62 (95% CI: 0.26-0.95) and 0.35 (95% CI: 0.03-0.71), respectively. Besides, higher participants had higher all-cancer SIRs. For males, SIRs were 1.08 (95% CI: 0.88-1.27) and 2.41 (95% CI: 2.05-2.78) in the lowest and highest quartiles of height, respectively. For females, SIRs were 1.03 (95% CI: 0.72-1.35) and 2.01 (95% CI: 1.66-2.58) in the lowest and highest quartiles of height, respectively. In this sample of participants living with newly diagnosed T2D, cancer incidence was higher among those who were taller, but also lower among those with higher BMI.